Clinical trials: gemcitabine hydrochloride
MIBC, mpMRI
Early Prediction of Neoadjuvant Chemotherapy Response in Bladder Cancer Using Quantitative Multiparametric MRI
Bladder cancer is a prevalent malignancy globally, with muscle-invasive disease having a five-year survival rate below 50%. Neoadjuvant chemotherapy (NAC) before radical cystectomy has shown efficacy for resectable…
- Conditions
- MIBC, mpMRI, NAC
- Trial name
- mpMRI (NCT07202845)
- Testing
- Multiparametric Magnetic Resonance Imaging (mpMRI)
- Where
- Egypt
- Volunteers
- 39 people
- Sponsor
- Assiut University
Carcinoma, Transitional Cell
Evaluation of Oxaliplatin and Gemcitabine in Patients With Metastatic Bladder Cancer
This phase II trial evaluated the impact of Oxaliplatin and Gemcitabine in patients with recurrent or advanced transitional cell carcinoma of the bladder.
- Trial name
- NCT04039867
- Testing
- Oxaliplatin with Gemcitabine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of California, Irvine
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer
Gamma-Secretase Inhibitor RO4929097 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors
This phase I trial is studying the side effects and best dose of gamma-secretase inhibitor RO4929097 when given together with gemcitabine hydrochloride in treating patients with advanced solid tumors.
- Conditions
- Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT01145456
- Testing
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, gemcitabine hydrochloride, pharmacological study
- Where
- 2 sites in Canada
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Borderline Resectable Pancreatic Cancer
Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer
This is a prospective, randomized phase II trial. Patients diagnosed with borderline resectable pancreatic adenocarcinoma will be randomly assigned to one of two treatment arms, either mFOLFIRINOX or gemcitabine and…
- Trial name
- NCT02241551
- Testing
- gemcitabine/nab-paclitaxel, mFOLFIRINOX
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Nathan Bahary, MD
Non-Small-Cell Lung Cancer
Pemetrexed and Gemcitabine Every 14 Days Versus Every 21 Days in Advanced Non Small Cell Lung Cancer
This study is designed to evaluate Pemetrexed and Gemcitabine Day 1 followed by Gemcitabine Day 8 every 21 days (Arm A) and Pemetrexed and Gemcitabine Day 1 every 14 days (Arm B) in patients with NSCLC.
- Trial name
- NCT00383331
- Testing
- Pemetrexed, Gemcitabine
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Eli Lilly and Company
Diffuse Large B Cell Lymphoma
Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL
Despite the current advances in clinical oncology, the prognosis of patients with resistant diffuse large B cell lymphoma or relapse after high dose chemotherapy is dismal.
- Trial name
- BeGeRN (NCT03259529)
- Testing
- Bendamustine hydrochloride, Gemcitabine 500 mg, Gemcitabine 700 mg
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL
The purpose of this study is to determine safety and tolerability of combination therapy of SGN-40 with gemcitabine and rituximab for the treatment of lymphoma.
- Trial name
- NCT00655837
- Testing
- SGN-40, rituximab, gemcitabine
- Where
- 9 sites in United States
- Volunteers
- 33 people
- Sponsor
- Seagen Inc.
Head and Neck Cancer
Gemcitabine and Carboplatin Followed By Laboratory-Treated T Lymphocytes in Treating Patients With Metastatic or Locally Recurrent Epstein-Barr Virus-Positive Nasopharyngeal Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00690872
- Testing
- autologous Epstein-Barr virus-specific cytotoxic T lymphocytes, carboplatin, gemcitabine hydrochloride
- Where
- Singapore
- Volunteers
- 35 people
- Sponsor
- National Cancer Centre, Singapore
Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma
Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This randomized phase II clinical trial studies how well gemcitabine hydrochloride and WEE1 inhibitor MK-1775 work compared to gemcitabine hydrochloride alone in treating patients with ovarian, primary peritoneal, or fallopian…
- Conditions
- Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Malignant Mixed Mesodermal (Mullerian) Tumor
- Trial name
- NCT02101775
- Testing
- Adavosertib, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis
- Where
- 16 sites in United States, Canada and 1 more
- Volunteers
- 124 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Pancreatic Adenocarcinoma
Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic Cancer
In the current study it is examined whether patients with good risk factors (age <75 years, total serum bilirubin < 1,5xULN, no history of cardiovascular diseases) treated with gemcitabine and erlotinib who developed skin rash of…
- Trial name
- ML22774 (NCT01729481)
- Testing
- Gemcitabine, Erlotinib, Oxaliplatin
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Pancreatic Acinar Carcinoma, Pancreatic Neoplasms
Acelarin First Line Randomised Pancreatic Study
The primary purpose of this study is to assess whether Acelarin (NUC-1031) is superior to gemcitabine in terms of overall survival for treatment of patients with metastatic pancreatic carcinoma.
- Trial name
- ACELARATE (NCT03610100)
- Testing
- Acelarin, Gemcitabine
- Where
- United Kingdom
- Volunteers
- 328 people
- Sponsor
- The Clatterbridge Cancer Centre NHS Foundation Trust
Ovarian Cancer
Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer
To compare outcomes between the CRS group and the control group in patients with recurrent epithelial ovarian cancer who have undergone chemotherapy
- Trial name
- KOV-02S (NCT07171528)
- Testing
- Secondary Cytoreductive Surgery
- Where
- South Korea
- Volunteers
- 80 people
- Sponsor
- National Cancer Center, Korea
Pancreatic Cancer
Fluorouracil, External-Beam Radiation Therapy, and Gemcitabine With or Without Brachytherapy Using Phosphorus P32 in Treating Patients With Locally or Regionally Advanced Unresectable Adenocarcinoma of the Pancreas
RATIONALE: Drugs used in chemotherapy, such as fluorouracil and gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00079365
- Testing
- fluorouracil, gemcitabine hydrochloride, brachytherapy
- Where
- United States
- Sponsor
- University of South Florida
Osteosarcoma, Pulmonary Metastases
Pulmonary Resectable Metastases of Osteosarcoma With Anti-angiogenics and CHemotherapy
The aim of this study is to evaluate the efficacy and safety of Second-line chemotherapy combined with Apatinib for the patients with resectable pulmonary metastasis of osteosarcoma.
- Conditions
- Osteosarcoma, Pulmonary Metastases, Apatinib
- Trial name
- PROACH (NCT03742193)
- Testing
- Apatinib, GD regimen
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Ruijin Hospital
Pancreatic Cancer
Fluorouracil, Gemcitabine, and Radiation Therapy in Treating Patients With Cancer of the Pancreas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003216
- Testing
- fluorouracil, gemcitabine hydrochloride, radiation therapy
- Where
- 107 sites in United States, Canada
- Volunteers
- 518 people
- Sponsor
- Radiation Therapy Oncology Group
Kidney Cancer
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00042965
- Testing
- capecitabine, gemcitabine hydrochloride
- Where
- 50 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Osteosarcoma
Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure
This is a randomized, controlled, open, multicenter phase III clinical study to evaluate the efficacy and safety of HS-20093 for injection versus gemcitabine in combination with docetaxel in patients with osteosarcoma who have at…
- Trial name
- NCT06935409
- Testing
- HS-20093, Gemcitabine combined with docetaxel
- Where
- 2 sites in China
- Volunteers
- 122 people
- Sponsor
- Hansoh BioMedical R&D Company
Transitional Cell Carcinoma
Neoadjuvant Chemotherapy Plus Nephroureterectomy for Locally Advanced Upper Tract Transitional Cell Cancer
The purpose of this study is to test the effectiveness, safety and side effects of two chemotherapy drugs (gemcitabine and cisplatin) when combined with surgery after chemotherapy for patients with upper urinary tract cancer.
- Trial name
- NCT00696007
- Testing
- Gemcitabine and cisplatin, Retrospective comparison
- Where
- United States
- Sponsor
- Lahey Clinic
Metastatic Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma
Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer
This phase III trial compares the effect of adding nivolumab to the usual chemotherapy (cisplatin or carboplatin with gemcitabine) versus standard chemotherapy alone in treating patients with nasopharyngeal cancer that has come…
- Conditions
- Metastatic Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Metastatic Nasopharyngeal Nonkeratinizing Carcinoma, Metastatic Nasopharyngeal Undifferentiated Carcinoma
- Trial name
- NCT04458909
- Testing
- Carboplatin, Cisplatin, Gemcitabine
- Where
- 325 sites in United States, Canada and 2 more
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Biliary Carcinoma
Panitumumab Plus Gemcitabine and Oxaliplatin (GEMOX)Versus GEMOX Alone to Treat Advanced Biliary Tract Adenocarcinoma
This is a multi-centre phase II, open-label, randomized (1:1), parallel-arm, study of panitumumab in combination with chemotherapy (P-GEMOX) versus chemotherapy alone (GEMOX).
- Trial name
- Vecti-BIL (NCT01389414)
- Testing
- Panitumumab plus GEMOX chemotherapy, GEMOX chemotherapy
- Where
- 12 sites in Italy
- Volunteers
- 89 people
- Sponsor
- Prof. Massimo Aglietta
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.